Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial
Authors:
- for the CAP-START study groupFGfor the CAP-START study group
- Douwe F. PostmaDPDouwe F. Postma
Open Access
- 10 January 2017
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 1-8
Abstract
To determine the cost-effectiveness of strategies of preferred antibiotic treatment with beta-lactam/macrolide combination or fluoroquinolone monotherapy compared to beta-lactam monotherapy. Costs and effects were estimated using data from a cluster-randomized cross-over trial of antibiotic treatment strategies, primarily from the reduced third payer perspective (i.e. hospital admission costs). Cost-minimization analysis (CMA) and cost-effectiveness analysis (CEA) were performed using linear mixed models. CMA results were expressed as difference in costs per patient. CEA results were expressed as incremental cost-effectiveness ratios (ICER) showing additional costs per prevented death. A total of 2,283 patients were included. Crude average costs within 90 days from the reduced third payer perspective were €4,294, €4,392, and €4,002 per patient for the beta-lactam monotherapy, beta-lactam/macrolide combination, and fluoroquinolone monotherapy strategy, respectively. CMA results were €106 (95% CI €-697 to €754) for the beta-lactam/macrolide combination strategy and €-278 (95%CI €-991 to €396) for the fluoroquinolone monotherapy strategy, both compared to the beta-lactam monotherapy strategy. The ICER was not statistically significantly different between the strategies. Other perspectives yielded similar results. There were no significant differences in cost-effectiveness of strategies of preferred antibiotic treatment of CAP on non-ICU wards with either beta-lactam monotherapy, beta-lactam/macrolide combination therapy, or fluoroquinolone monotherapy. The trial was registered with ClinicalTrials.gov, number NCT01660204 , on May 2nd, 2012.Keywords
Funding Information
- ZonMw (171202002)
This publication has 15 references indexed in Scilit:
- Antibiotic Treatment Strategies for Community-Acquired Pneumonia in AdultsNew England Journal of Medicine, 2015
- β-Lactam Monotherapy vs β-Lactam–Macrolide Combination Treatment in Moderately Severe Community-Acquired PneumoniaJAMA Internal Medicine, 2014
- Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysisBMC Infectious Diseases, 2014
- UPDATE OF THE DUTCH MANUAL FOR COSTING IN ECONOMIC EVALUATIONSInternational Journal of Technology Assessment in Health Care, 2012
- The Design of Cluster Randomized Crossover TrialsJournal of Educational and Behavioral Statistics, 2011
- Clinical and economic burden of community-acquired pneumonia among adults in EuropeThorax, 2010
- Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled studyThe Lancet, 2007
- A Review of New FluoroquinolonesTreatments in Respiratory Medicine, 2006
- A Review of Streptococcus pneumoniae Infection Treatment Failures Associated with Fluoroquinolone ResistanceClinical Infectious Diseases, 2005
- The Burden of Community‐Acquired Pneumonia in Seniors: Results of a Population‐Based StudyClinical Infectious Diseases, 2004